Palm Therapeutics

Pioneering first-in-class medicines that block protein palmitoylation, unlocking undruggable targets in oncology, immunology, and inflammatory diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Diego, CA 92101, USA
  • Currency USD
  • Founded January 2021
  • Employees 2
  • Incorporation Type C-corp
  • Website palmtherapeutics.com

Company Summary

Palm Therapeutics is developing small molecule therapies that exploit the mechanism of protein palmitoylation to inhibit previously undruggable targets. Our lead program is an NRAS palmitoylation inhibitor for NRAS-mutant cancers (~500,000 patients in the U.S.). Palm has secured $1.3M in funding through SBIR and nonprofit grants, and recently closed a $700k Pre-Seed led by Tachyon Ventures.

Team

  • Cofounder & CEO

    Dr. Rudd’s career has centered around developing chemical tools to interrogate biological lipids and their roles in health and disease. He received his Ph.D. in chemistry from UC San Diego, where he authored eight high-impact papers and was the recipient of several awards. Dr. Rudd developed the first small molecule probes for directly inhibiting protein palmitoylation in cells. He is a JLABS resident and a Servier FAST Discovery Award winner.

  • Scientific Cofounder

    Dr. Devaraj is a Professor and Murray Goodman Endowed Chair in Chemistry and Biochemistry at the University of California San Diego. His lab has extensive expertise in the chemical biology of lipids and the development of membrane-based chemistries. His work has been recognized by several prestigious awards, including the American Chemical Society Award in Pure Chemistry, the Eli Lilly Award in Biological Chemistry, and a Guggenheim Fellowship.

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free